ArticleESMO open2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
ArticleESMO open2022
N Girard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.